[go: up one dir, main page]

WO2001002031A3 - Traitement anti-calcification cible - Google Patents

Traitement anti-calcification cible Download PDF

Info

Publication number
WO2001002031A3
WO2001002031A3 PCT/US2000/017606 US0017606W WO0102031A3 WO 2001002031 A3 WO2001002031 A3 WO 2001002031A3 US 0017606 W US0017606 W US 0017606W WO 0102031 A3 WO0102031 A3 WO 0102031A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
treatments
targeted agents
targeted
calcification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/017606
Other languages
English (en)
Other versions
WO2001002031A2 (fr
Inventor
Dan Simionescu
Agneta Simionescu
Jean-Marie Girardot
Marie-Nadia Girardot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomedical Design Inc
Original Assignee
Biomedical Design Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedical Design Inc filed Critical Biomedical Design Inc
Priority to AU56397/00A priority Critical patent/AU5639700A/en
Publication of WO2001002031A2 publication Critical patent/WO2001002031A2/fr
Publication of WO2001002031A3 publication Critical patent/WO2001002031A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés permettant de conférer aux biomatériaux une résistance accrue à la calcification, grâce à un traitement au moyen d'agents à ciblage cellulaire et/ou à ciblage matriciel. En l'occurrence, on utilise des agents à ciblage cellulaire qui bloquent les canaux calcium, ou qui préviennent l'atteinte oxydative des cellules, et/ou qui inhibent des enzymes. D'autres traitements des biomatériaux permettent d'éliminer des composants de liaison au calcaire issus des cellules, ou cibler des matrices extracellulaire, notamment par un clivage de protéines au moyen du bromure de cyanogène, ou par réduction des liaisons bisulfure donnant des groupes sulfhydryles qui sont ensuite alkylés. Différentes combinaisons de ces traitements permettent également d'augmenter la résistance à la calcification de tissus cardio-vasculaires ayant préalablement subi des traitements de fixation chimique ou d'anti-calcification.
PCT/US2000/017606 1999-07-01 2000-06-27 Traitement anti-calcification cible Ceased WO2001002031A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56397/00A AU5639700A (en) 1999-07-01 2000-06-27 Targeted anticalcification treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14217199P 1999-07-01 1999-07-01
US60/142,171 1999-07-01

Publications (2)

Publication Number Publication Date
WO2001002031A2 WO2001002031A2 (fr) 2001-01-11
WO2001002031A3 true WO2001002031A3 (fr) 2001-12-06

Family

ID=22498818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/017606 Ceased WO2001002031A2 (fr) 1999-07-01 2000-06-27 Traitement anti-calcification cible

Country Status (2)

Country Link
AU (1) AU5639700A (fr)
WO (1) WO2001002031A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900294B2 (en) 2002-01-04 2014-12-02 Colibri Heart Valve Llc Method of controlled release of a percutaneous replacement heart valve
US9119738B2 (en) 2010-06-28 2015-09-01 Colibri Heart Valve Llc Method and apparatus for the endoluminal delivery of intravascular devices

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078163B2 (en) 2001-03-30 2006-07-18 Medtronic, Inc. Process for reducing mineralization of tissue used in transplantation
US7955788B2 (en) 2003-10-30 2011-06-07 Medtronic, Inc. Bioprosthetic tissue preparation with synthetic hydrogels
CA2820738C (fr) 2010-12-14 2019-01-15 Colibri Heart Valve Llc Valvule cardiaque apte a etre posee par voie percutanee, comprenant des valves a membranes repliees a feuillets integres
RU2597564C1 (ru) * 2015-06-17 2016-09-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний" (НИИ КПССЗ) Способ прогнозирования риска кальцификации биологических протезов клапанов сердца
WO2019051476A1 (fr) 2017-09-11 2019-03-14 Incubar, LLC Dispositif d'étanchéité destiné à être utilisé comme implant vasculaire de conduit pour réduire l'endofuite

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
EP0564786A2 (fr) * 1992-02-12 1993-10-13 Lifecell Corporation Procédé pour le traitement et la conservation de tissus à base de collagène pour la transplantation
WO1996013227A1 (fr) * 1994-10-21 1996-05-09 University Of Michigan Tissus bioprothetiques resistants a la calcification et procedes d'obtention
US5558875A (en) * 1994-06-06 1996-09-24 Wang; Su Method of preparing collagenous tissue
US5843182A (en) * 1994-03-14 1998-12-01 Cryolife, Inc. Treated tissue for implantation and methods of preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
EP0564786A2 (fr) * 1992-02-12 1993-10-13 Lifecell Corporation Procédé pour le traitement et la conservation de tissus à base de collagène pour la transplantation
US5843182A (en) * 1994-03-14 1998-12-01 Cryolife, Inc. Treated tissue for implantation and methods of preparation
US5558875A (en) * 1994-06-06 1996-09-24 Wang; Su Method of preparing collagenous tissue
WO1996013227A1 (fr) * 1994-10-21 1996-05-09 University Of Michigan Tissus bioprothetiques resistants a la calcification et procedes d'obtention

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HENRY P D: "ANTI-ATHEROSCLEROTIC EFFECTS OF CALCIUM ANTAGONISTS: A BRIEF REVIEW", CLINICAL AND INVESTIGATIVE MEDICINE, vol. 10, no. 6, 1 November 1987 (1987-11-01), pages 601 - 605, XP000604021 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900294B2 (en) 2002-01-04 2014-12-02 Colibri Heart Valve Llc Method of controlled release of a percutaneous replacement heart valve
US9125739B2 (en) 2002-01-04 2015-09-08 Colibri Heart Valve Llc Percutaneous replacement heart valve and a delivery and implantation system
US9186248B2 (en) 2002-01-04 2015-11-17 Colibri Heart Valve Llc Percutaneously implantable replacement heart valve device and method of making same
US9554898B2 (en) 2002-01-04 2017-01-31 Colibri Heart Valve Llc Percutaneous prosthetic heart valve
US9119738B2 (en) 2010-06-28 2015-09-01 Colibri Heart Valve Llc Method and apparatus for the endoluminal delivery of intravascular devices

Also Published As

Publication number Publication date
AU5639700A (en) 2001-01-22
WO2001002031A2 (fr) 2001-01-11

Similar Documents

Publication Publication Date Title
WO2005055944A3 (fr) Composition d'oligosaccharides et leur utilisation dans le traitement d'infection
AU1101801A (en) Compositions for treating shoes and methods and articles employing same
WO2004031350A3 (fr) Modulation de l'expression du gene forkhead box o1a
ATE347277T1 (de) Zusammensetzung mit bakteriostatischen und bakteriziden eigenschaften gegen bakterielle sporen und zellen und verfahren zu deren verwendung zur behandlung von lebensmitteln
DE60231395D1 (de) Dezellularisierung von gewebematrixen
IL73533A (en) Enzyme-resistant immunomodulatory peptides,and their preparation
CA2387198A1 (fr) Methode de traitement de la perte de cheveux a l'aide de composes thyromimetiques
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
WO2008109165A3 (fr) Membranes de régénération osseuse guidée minéralisées et procédés pour les fabriquer
WO2001002031A3 (fr) Traitement anti-calcification cible
AU5638200A (en) Tissue products having antiviral properties
WO2002089730A3 (fr) Composes et procedes de modulation de cd154
WO2004029137A3 (fr) Matrices de polymere reticule et procede de fabrication de celles-ci
WO2002030357A3 (fr) Composes et procedes servant a moduler la fonction de ccr4
BRPI0416088A (pt) composição, sistema, e método de tratar condições tais como calcificação vascular
WO2005014607A3 (fr) Modulation antisens de l'expression de la stearoyl-coa desaturase
MX2010003349A (es) Metodo de desgomado de yute con enzima compleja aplicada (1).
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
CY1112119T1 (el) Μεθοδος για πατιναρισμα χαλκου
BR0210522A (pt) Processo para tratamento de carcaça de animal
WO2003012031A3 (fr) Modulation antisens de l'expression de la stearoyl-coa desaturase
DE69923559D1 (de) Methoden zur inhibierung von helicobacter pylori
AU2002233951A1 (en) Compositions for pre-treating shoes and methods and articles employing same
UA94231C2 (ru) Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли
AU4643501A (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP